Stefan Bornstein appointed as Transcampus Dean
King’s College London has appointed Professor Stefan Bornstein as Transcampus Dean (King’s College London and Technische Universität Dresden), with immediate effect.
The role of Transcampus Dean is the first of its kind for King’s, with a focused remit to drive collaborative research initiatives between the two named universities. Reporting to Professor Simon Howell, Executive Dean, Faculty of Life Sciences & Medicine, this key appointment formalises Professor Bornstein's leadership of the emerging strategic partnership between King's and the TU Dresden.
Since 2013, he has led an exciting initiative to create a ‘transcampus’ for research between the two universities, on being appointed Chair and Honorary Consultant in Diabetes & Endocrinology at King’s. To date, this work has focused on two strategic research areas: Diabetes and Haematology. He will continue to coordinate his work at King’s alongside his roles as Director and Chair of the Department of Medicine at the TU Dresden.
Professor Bornstein is best known for his pioneering work on the endocrine stress system, being the first researcher to describe comprehensively the correlation of the hormones adrenalin and cortisol in health and disease. A pioneer of therapeutic approaches to diabetes in preclinical and clinical stages, Professor Bornstein has worked closely with the Nobel laureates Andrew V Schally and Rita Levi Montalcini.
In 2012 he was responsible for the first ever implantation of an artificial pancreas system in a patient with type-1 diabetes to restore insulin production. This innovative clinical strategy could revolutionise diabetes therapy: patients would not be required to take immunosuppressive drugs which are necessary for current pancreas transplants, offering them a better quality of life and lessen their susceptibility to infections and other adverse effects of taking this medication.
Professor Bornstein graduated in Medicine from the University of Ulm and Miami in 1988. He completed his residency in internal medicine in 1994 and specialised in endocrinology and diabetes. He has since worked as a research scholar and acting unit chief at the endocrine branch at the National Institutes of Health in Bethesda, United States. From 2001 to 2004 he was Professor and Vice-Chair of the Department of Endocrinology and Metabolism at the University of Düsseldorf, Germany. In 2004, he was appointed to Director and Chair of the Department of Medicine at the TU Dresden where, in 2012, he also become Dean of International Affairs and Development.
Professor Bornstein has won several notable awards including the first prize for 'The new generation of academics' and Marius-Tausk-Award of the German Society of Endocrinology. He is also a recipient of the Heisenberg Award of the German Research Foundation (DFG). He has (co)authored more than 500 scientific papers and contributed to numerous books.
His research attracts significant funding from a range of sources including the EU, NIH, DFG (the German Ministry of Health), charitable foundations and industry. His current research interests primarily focus on lipid-, steroid- and catecholamine metabolism, immune endocrine crosstalk, type 1 diabetes, islet transplantation and mechanisms of hypertension in the metabolic syndrome.
Professor Sir Robert Lechler, Vice-Principal (Health) and Executive Director, King’s Health Partners, comments: ‘I look forward to a real strengthening of King’s relationship with the TU Dresden, enabled by Stefan’s work in this exciting role. With his proven track record of leveraging strong international partnerships, he will play a key part in supporting King’s strategy to firmly place the university at the centre of a mutually-beneficial network of global partners dedicated to solving world problems.’
Professor Howell says: ‘Stefan’s passion and experience in translating medical research into new treatments for patients alongside his strong academic leadership record make this an exceptional appointment for King’s and the TU Dresden. Both universities share a goal of achieving world-class excellence in health research and this close alignment will help to realise opportunities offered by this partnership.’
Professor Bornstein says: ‘I am looking forward to driving forward the transcampus project, which has great potential to flourish and contribute strongly to the overarching missions of both universities. I am particularly pleased to be able to announce, in turn, the appointment of two new part-time Chairs who will take leading roles in developing the transcampus initiative. Professor Andreas Birkenfeld, who has existing collaborations with Professor Mark Peakman in King’s Division of Diabetes & Nutritional Sciences, will lead on the Diabetes stream. And Professor Martin Bornhäuser, a close collaborator of Professor Ghulam Mufti, Head of the Section of Haemato-oncology in the Division of Cancer Studies, will take a lead on developing initiatives in Haematology.’
Professor Bornstein’s work will be supported by a part-time Project Coordinator, Dr Virginia Kamvissi.